The director of the Center for Biologics Evaluation Research at the FDA provided an overview of the Keynote Address he gave at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference. [WATCH TIME: 3 minutes]
The senior investigator in the Neuromuscular and Neurogenetic Disorders of Childhood Section at NINDS shared his perspective on the data coming out of neuromuscular research and the promise of genetic medicine. [WATCH TIME: 2 minutes]
In recognition of World MS Day, Meghan Beier, PhD, MA, a health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine, discussed the effects of multiple sclerosis (MS) on cognitive function.
At CMSC 2023, the neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed the importance of early intervention in speech and communication therapy, as well as the challenges faced in getting patients to seek therapy at the time of diagnosis. [WATCH TIME: 5 minutes]
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]
The field of Alzheimer disease has entered a new era of earlier detection, creating an opportunity to redefine treatment and the clinical care of patients.
Although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of PD to this day, gait dysfunction remains a difficult symptom to treat.
Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
Episode 9 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Larry B. Goldstein, MD, of University of Kentucky Medical Center. [WATCH TIME: 8 minutes]
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]
As the most common trigeminal autonomic cephalalgia, this unilateral and severe headache is accompanied by ipsilateral autonomic features and is often challenging to treat.
The assistant professor, Rutgers University, New Brunswick, New Jersey, offers an overview on her ongoing lab project about a music-based intervention to improve insomnia in dementia and caregivers. [WATCH TIME: 3 minutes]
A panel of experts considers current unmet needs in SMA by emphasizing the need for further study of combination therapy, more comprehensive newborn screening, and more effective early diagnosis and treatment.
Episode 3 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Mehmood Rashid, MD, of University of Toledo. [WATCH TIME: 4 minutes]
The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
The director of clinical outcomes and research development in neurology at Stanford University spoke about the paradigm shift in neuromuscular therapy interventions at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).
The director of the center for gene therapy at Nationwide Children's Hospital talked about the challenges and opportunities of gene therapies for neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 4 minutes]
The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.
At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]
The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]
Tanuja Chitnis, MD and Lauren B. Krupp, MD give insight into the future of pediatric multiple sclerosis by discussing unmet needs and advice for community neurologists.
For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.
Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.
The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]